| Xie et al. 2015 [33] |
Excluded |
Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human NSCLC. |
| Xu et al. 2015 [34] |
Excluded |
Bisdemethoxycurcumin effects on TGF-β1 induced EMT in NSCLC are mediated through WIF-1 |
| Tan et al. 2013 [32] |
Excluded |
miR-29s suppress the Wnt signaling pathway through demethylation of WIF-1 in NSCLC. |
| Liu et al. 2011 [35] |
Excluded |
Hypomethylation effects of curcuminoid on WIF-1 promoter in NSCLC cell lines. |
| Liu et al. 2011a [12] |
Excluded |
Hypomethylation agent induces apoptosis in human NSCLC |
| Suzuki et al. 2010 [36] |
Included |
Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related NSCLC through WIF-1aberrant methylation and Alterations of EGFR Signaling. |
| Gao et al. 2009 [37] |
Excluded |
The role of Epigallocatechin-3- gallate in the reversal of WIF-1 promoter methylation in NSCLC cell line |
| Gao et al. 2009a [38] |
Excluded |
Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells |
| Yoshino et al. 2009 [20] |
Included |
Promoter hypermethylation of the p16 and WIF-1genes as an independent prognostic marker in stage IA NSCLC. |
| Yang et al. 2009 [39] |
Excluded |
The role WIF-1 promoter hypermethylation in the diagnosis of NSCLC-related malignant pleural effusion. |
| Ren et al. 2007 [9] |
Included |
The relationship between WIF-1, Gsk-3β and nm23-H1 expression and the prognosis in patient with non-small cell lung cancer. |
| Mazieres et al. 2004 [19] |
Included |
Promoter Hypermethylation in Human lung cancer. |
